This is an unofficial archive of PsychonautWiki as of 2025-08-11T15:14:44Z. Content on this page may be outdated, incomplete, or inaccurate. Please refer to the original page for the most up-to-date information.
2C-B: Difference between revisions
>Mattyboi m Added descriptions to a few effects |
>Larnaca m Undo revision 165675 by Vsalamanca00 (talk) |
||
| (8 intermediate revisions by 6 users not shown) | |||
| Line 4: | Line 4: | ||
It is perhaps the most well-known member of the [[2C-x family]], which are structurally related to the classical psychedelic [[mescaline]]. The mechanism of action is not fully known, although [[serotonin]] [[receptor]] binding activity is thought to be principally involved. | It is perhaps the most well-known member of the [[2C-x family]], which are structurally related to the classical psychedelic [[mescaline]]. The mechanism of action is not fully known, although [[serotonin]] [[receptor]] binding activity is thought to be principally involved. | ||
2C-B was discovered in 1974 by the American chemist [[Alexander Shulgin]], who was investigating psychedelic phenethylamines derived from mescaline.<ref name="PiHKAL">{{cite book|title=PiHKAL: A Chemical Love Story|title-link=PiHKAL|author-link1=Alexander Shulgin|author1=Alexander Shulgin|author2=Ann Shulgin|year=1991|publisher=Transform Press|location=United States|isbn=0963009605|oclc=1166889264|chapter-url=https://erowid.org/library/books_online/pihkal/pihkal020.shtml|chapter=#20. 2C-B}}</ref><ref>{{cite journal|last1=Shulgin|first1=A. T.|author-link1=Alexander Shulgin|last2=Carter|first2=M. F.|title=Centrally active phenethylamines|journal=Psychopharmacology Communications|year=1975|volume=1|issue=1|pages=93–98|pmid=1223994|issn=0098-616X|oclc=924603662}}</ref> | 2C-B was discovered in 1974 by the American chemist [[Alexander Shulgin]], who was investigating psychedelic phenethylamines derived from [[mescaline]].<ref name="PiHKAL">{{cite book|title=PiHKAL: A Chemical Love Story|title-link=PiHKAL|author-link1=Alexander Shulgin|author1=Alexander Shulgin|author2=Ann Shulgin|year=1991|publisher=Transform Press|location=United States|isbn=0963009605|oclc=1166889264|chapter-url=https://erowid.org/library/books_online/pihkal/pihkal020.shtml|chapter=#20. 2C-B}}</ref><ref>{{cite journal|last1=Shulgin|first1=A. T.|author-link1=Alexander Shulgin|last2=Carter|first2=M. F.|title=Centrally active phenethylamines|journal=Psychopharmacology Communications|year=1975|volume=1|issue=1|pages=93–98|pmid=1223994|issn=0098-616X|oclc=924603662}}</ref> | ||
In the 1970s, it first saw use as a therapeutic aid by a small circle of American psychotherapists and was considered one of the best substances for this purpose due to its short duration, relative absence of side effects, and comparably mild nature.<ref>{{cite web|title=2C-B: Effects|url=http://www.erowid.org/chemicals/2cb/2cb_effects.shtml|publisher=Erowid|access-date=February 10, 2020|orig-year=Modified 2015|date=February 12, 1998}}</ref> | In the 1970s, it first saw use as a therapeutic aid by a small circle of American psychotherapists and was considered one of the best substances for this purpose due to its short duration, relative absence of side effects, and comparably mild nature.<ref>{{cite web|title=2C-B: Effects|url=http://www.erowid.org/chemicals/2cb/2cb_effects.shtml|publisher=Erowid|access-date=February 10, 2020|orig-year=Modified 2015|date=February 12, 1998}}</ref> | ||
| Line 13: | Line 13: | ||
Smaller doses (under 15 mg) are reported to be useful as a sensory and aesthetic enhancer (in a manner somewhat similar to [[MDMA]]) while larger doses are reported to produce a distinct mind-manifesting psychedelic effect. | Smaller doses (under 15 mg) are reported to be useful as a sensory and aesthetic enhancer (in a manner somewhat similar to [[MDMA]]) while larger doses are reported to produce a distinct mind-manifesting psychedelic effect. | ||
While more research is needed, it is generally thought to be physiologically well-tolerated. It likely has a [[Psychedelics#Toxicity and harm potential|safety profile similar to classical psychedelics]], which are known to have low abuse potential and toxicity. However, adverse psychological reactions such as severe [[anxiety]], [[paranoia]], [[delusions]], [[psychosis]] are always possible, particularly for those predisposed to mental disorders.<ref>{{cite journal|last=Strassmann|first=Rick|title=Adverse reactions to psychedelic drugs. A review of the literature|journal=Journal of Nervous and Mental Disease|volume=172|issue=10|pages=577–595|doi=10.1097/00005053-198410000-00001|pmid=6384428|year=1984|issn=0022-3018|oclc=1754691}}</ref> | While more research is needed, it is generally thought to be physiologically well-tolerated{{Citation needed}}. It likely has a [[Psychedelics#Toxicity and harm potential|safety profile similar to classical psychedelics]], which are known to have low abuse potential and toxicity. However, adverse psychological reactions such as severe [[anxiety]], [[paranoia]], [[delusions]], [[psychosis]] are always possible, particularly for those predisposed to mental disorders.<ref>{{cite journal|last=Strassmann|first=Rick|title=Adverse reactions to psychedelic drugs. A review of the literature|journal=Journal of Nervous and Mental Disease|volume=172|issue=10|pages=577–595|doi=10.1097/00005053-198410000-00001|pmid=6384428|year=1984|issn=0022-3018|oclc=1754691}}</ref> | ||
It is highly advised to use [[harm reduction practices]] if using this substance. | It is highly advised to use [[harm reduction practices]] if using this substance. | ||
| Line 26: | Line 26: | ||
Shortly after gaining traction in the underground psychotherapy community, 2C-B became popular in the recreational drug scene. It was well-liked as a [[MDMA]] substitute in raves and club parties due to its minimal comedown and a clear, euphoric headspace. | Shortly after gaining traction in the underground psychotherapy community, 2C-B became popular in the recreational drug scene. It was well-liked as a [[MDMA]] substitute in raves and club parties due to its minimal comedown and a clear, euphoric headspace. | ||
In the 1980s and early 1990s, several foreign companies legally manufactured the substance under the brand names "Nexus", "Erox", and "Performax" and advertised that it would alleviate impotence, frigidity, and diminished libido. It was sold at adult book and video stores, "head" shops, and some nightclubs. The DEA reported its distribution in Miami, Florida in the form of yellow pills marketed as an aphrodisiac. | In the 1980s and early 1990s, several foreign companies legally manufactured the substance under the brand names "Nexus", "Erox", and "Performax" and advertised that it would alleviate impotence, frigidity, and diminished libido. It was sold at adult book and video stores, "head" shops, and some nightclubs. The DEA reported its distribution in Miami, Florida in the form of yellow pills marketed as an aphrodisiac.<ref>https://www.justice.gov/archive/ndic/pubs0/665/665p.pdf</ref> | ||
In the United States, it gained popularity as an alternative to MDMA after the latter was classified as a Schedule I substance in 1985. The increasing popularity of 2C-B led to it also being placed in Schedule I in 1995.<ref name="DEA2001" /> It saw a resurgence in interest in the 2000s, with the advent of the [[research chemicals|"research chemicals"]]/"designer drugs" scene and darknet markets. | In the United States, it gained popularity as an alternative to MDMA after the latter was classified as a Schedule I substance in 1985. The increasing popularity of 2C-B led to it also being placed in Schedule I in 1995.<ref name="DEA2001" /> It saw a resurgence in interest in the 2000s, with the advent of the [[research chemicals|"research chemicals"]]/"designer drugs" scene and darknet markets. | ||
| Line 57: | Line 57: | ||
*'''[[Effect::Appetite suppression]]''' - While not as intense as stimulants such as [[MDMA]], most doses can cause a decrease in appetite. | *'''[[Effect::Appetite suppression]]''' - While not as intense as stimulants such as [[MDMA]], most doses can cause a decrease in appetite. | ||
*'''[[Effect::Bodily control enhancement]]''' | *'''[[Effect::Bodily control enhancement]]''' | ||
*'''[[Effect::Increased blood pressure]]''' | *'''[[Effect::Increased blood pressure]]'''<ref>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5859368/</ref> | ||
*'''[[Effect::Increased bodily temperature]]'''{{citation needed}} | *'''[[Effect::Increased bodily temperature]]'''{{citation needed}} | ||
*'''[[Effect::Increased heart rate]]''' | *'''[[Effect::Increased heart rate]]'''<ref>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5859368/</ref> | ||
*'''[[Effect::Increased perspiration]]''' | *'''[[Effect::Increased perspiration]]''' | ||
*'''[[Effect::Dehydration]]'''{{citation needed}} | *'''[[Effect::Dehydration]]'''{{citation needed}} | ||
| Line 266: | Line 266: | ||
*[https://erowid.org/chemicals/2cb/2cb.shtml 2C-B (Erowid Vault)] | *[https://erowid.org/chemicals/2cb/2cb.shtml 2C-B (Erowid Vault)] | ||
*[https://isomerdesign.com/PiHKAL/read.php?domain=pk&id=20 2C-B (PiHKAL / Isomer Design)] | *[https://isomerdesign.com/PiHKAL/read.php?domain=pk&id=20 2C-B (PiHKAL / Isomer Design)] | ||
*[https://go.drugbank.com/drugs/DB01537 2C-B (DrugBank)] | |||
===Discussion=== | ===Discussion=== | ||